
BriaCell Therapeutics ( ($TSE:BCT) ) has provided an announcement. BriaCell reported preclinical data indicating Bria-OTS+ activated innate and adaptive immunity, enhanced cancer-cell killing after priming and boosting, and retained cytotoxic
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| BCTX | BriaCell Therapeutics | 3.06 | -4.94 | -61.75% |
| Name | Price | % Change | |
|---|---|---|---|
| $3.06 | -61.75% |

BriaCell Therapeutics ( ($TSE:BCT) ) has provided an announcement. BriaCell reported preclinical data indicating Bria-OTS+ activated innate and adaptive immunity, enhanced cancer-cell killing after priming and boosting, and retained cytotoxic

BriaCell Therapeutics ( ($TSE:BCT) ) has shared an announcement. BriaCell and BriaPro announced four preclinical presentations at the Society for Immunotherapy of Cancer’s 2026 annual meeting. The research covered Bria-OTS+

BriaCell Therapeutics ( ($TSE:BCT) ) has issued an update. BriaCell Therapeutics reported new clinical biomarker data at the ESMO 2026 Congress from a pooled analysis of 111 heavily pretreated metastatic

BriaCell (BCTX) announced the presentation of clinical biomarker findings from a prospective pooled analysis of patients with metastatic breast cancer, or MBC, treated with immune based therapies including the BriaCell

BriaCell (BCTX) announced that the independent Data Safety Monitoring Board, or DSMB, has issued its seventh consecutive recommendation following review of clinical data from BriaCell’s Phase 3 Bria-ABC study of

BriaCell Therapeutics ( ($TSE:BCT) ) just unveiled an update. BriaCell Therapeutics has advanced its personalized melanoma immunotherapy vaccine candidate, Bria-MEL+, achieving a key genetic engineering milestone that moves the program

BriaCell (BCTX) announced that Bria-MEL+, its personalized whole cell melanoma immunotherapy vaccine candidate, has achieved a genetic engineering milestone, advancing the program toward clinical development. Bria-MEL+ is a cell-based therapeutic

BriaCell (BCTX) Therapeutics announced that the FDA has completed its review of the Investigational New Drug application for Bria-PROS+ and issued a Study May Proceed letter, clearing the way for

An update from BriaCell Therapeutics ( ($TSE:BCT) ) is now available. Source Rock Royalties Ltd. has declared a monthly cash dividend of $0.0065 per common share, payable on August 14,

BriaCell (BCTX) announced that the Odette Cancer Centre at Sunnybrook Health Sciences Centre has joined BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Dec 10, 2026TBA | $28.33M | ― | ― | 0.01 | -0.33 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.